The global sales and marketing agreement establishes a preferred collaboration between Hoya Vision Care and Haag-Streit to provide eye care professionals (ECPs) with Lenstar Myopia by Hoya to provide diagnostics and treatment for myopia.
By providing information and education to patients and their parents about myopia and its progression, ECPs will be able to establish their myopia management capabilities using Lenstar Myopia by Hoya, which is based on the technology of the Lenstar 900 optical biometer and the corresponding EyeSuite myopia management software platform.
This, combined with Hoya Vision Care's MiyoSmart spectacle lens, which was introduced in 2018 using Defocus Incorporated Multiple Segments (D.I.M.S.) Technology.
This technology has been clinically proven to slow myopia progression in children aged 8 to 13, while creating a powerful one-two approach to diagnose and manage myopia. MiyoSmart has now been used to treat over 500,000 patients.
“The strategic partnership with Haag-Streit aligns with one of Hoya Vision Care’s core missions to provide information and innovative solutions to our valued ECP’s who are on the front lines as we globally address the rapidly growing problem of myopia in children,” said Alexandre Montague, CEO, Hoya Vision Care.
“By bringing together our organizations technologies and solutions we are creating a seamless approach for our ECP business partners to expand their myopia management capabilities and tackle this growing global epidemic.”
As myopia continues to rise around the world, this partnership creates a preferred partner status between the two companies, allowing them to deliver diagnoses and treatment for myopia to as many ECPs as possible.
Currently, Lenstar Myopia is being utilized by Hoya ECPs in China with planned distribution expansion into APAC, EMEA and Canada in the near future.